CEACAM5 and colorectal carcinoma: By combining this approach with an assessment of the conventional serum molecular biomarker CEA, this study aimed to investigate whether any combination of these three biomarkers (i.e., the CD45neg EpCAMpos CTC count, CD45neg EpCAMneg cell count, or CEA level) could improve the predictive performance for CRC or its status.